(Q43634469)

25 November 2017

Liposomal daunorubicin in the treatment of relapsed or refractory non-Hodgkin's lymphoma (English)

1 reference

25 November 2017

1 reference

A Tulpule

1

1 reference

25 November 2017

M U Rarick

2

1 reference

25 November 2017

J Kolitz

3

1 reference

25 November 2017

J Bernstein

4

1 reference

25 November 2017

A Myers

5

1 reference

25 November 2017

L A Buchanan

6

1 reference

25 November 2017

B M Espina

7

1 reference

25 November 2017

A Traynor

8

1 reference

25 November 2017

J Letzer

9

1 reference

25 November 2017

G R Justice

10

1 reference

25 November 2017

D McDonald

11

1 reference

25 November 2017

L Roberts

12

1 reference

25 November 2017

W Boswell

13

1 reference

25 November 2017

B Nathwani

14

1 reference

25 November 2017

A M Levine

15

1 reference

25 November 2017

1 April 2001

1 reference

25 November 2017

1 reference

25 November 2017

12

1 reference

25 November 2017

4

1 reference

25 November 2017

457-462

1 reference

Karnofsky memorial lecture. The low-grade non-Hodgkin's lymphomas: challenges and opportunities

25 November 2017

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1011181016401

7 January 2021

Comparison of combined and single-agent chemotherapy in non-Hodgkin's lymphoma of favourable histological type

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1011181016401

7 January 2021

Pharmacokinetics of liposome-encapsulated anti-tumor drugs. Studies with vinblastine, actinomycin D, cytosine arabinoside, and daunomycin

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1011181016401

7 January 2021

Phase I and pharmacologic study of liposomal daunorubicin (DaunoXome).

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1011181016401

7 January 2021

Phase I/II clinical and pharmacokinetic evaluation of liposomal daunorubicin

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1011181016401

7 January 2021

Randomized phase III trial of liposomal daunorubicin versus doxorubicin, bleomycin, and vincristine in AIDS-related Kaposi's sarcoma

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1011181016401

7 January 2021

Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1011181016401

7 January 2021

National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas: summary and description of a working formulation for clinical usage. The Non-Hodgkin's Lymphoma Pathologic Classification Project

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1011181016401

7 January 2021

New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1011181016401

7 January 2021

Phase II trial of fludarabine phosphate in lymphoma: an effective new agent in low-grade lymphoma

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1011181016401

7 January 2021

2-Chlorodeoxyadenosine is an active salvage therapy in advanced indolent non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1011181016401

7 January 2021

Cladribine in the treatment of advanced relapsed or refractory low and intermediate grade non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1011181016401

7 January 2021

Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1011181016401

7 January 2021

Risk factors for doxorubicin-induced congestive heart failure

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1011181016401

7 January 2021

Identifiers

DOI

10.1023/A:1011181016401

1 reference

25 November 2017

1 reference